Industry-Sponsored Research Week
University-Industry Engagement Advisor

Columbia partnering with Kedrion Biopharma to develop new IgG therapy for COVID-19

By David Schwartz
Published: July 28th, 2020

Italian biopharma company Kedrion Biopharma, a major player in plasma-derived therapies, has signed a research partnership with Columbia University Irving Medical Center to develop and test a new IgG therapy for COVID-19. The therapy is being co-developed by Kedrion and Kamada Ltd, an Israeli company that also specializes in plasma derived products.

The agreement calls for Kedrion to supply Columbia with convalescent plasma from patients who have recovered from COVID-19, which will be used to manufacturing IgG therapy. Columbia University will test the convalescent plasma against viral proteins to check the neutralizing power of the hyperimmune Immunoglobins.

Dr. Steven Spitalnik, medical director of the Clinical Laboratories at Columbia University Irving Medical Center, said the evaluation should be completed by early August, and human clinical trials may be initiated pending FDA authorization.

“We hope to be able to evaluate the first assays in a week or two,” Spitalnik reports. “Then during this third quarter we hope to evaluate the IgG therapy that could be used for clinical studies in patients and volunteers.” He hopes the therapy can be given to frontline healthcare workers at risk for COVID-19 at Columbia University Irving Medical Center and elsewhere.

Kedrion CEO Paolo Marcucci said he welcomed the partnership. “We are proud to work with Columbia on a project that could ultimately help patients in need and perhaps even help frontline medical workers at Columbia itself. That would be wonderful,” he said.

Source: Cision

U.S. Export Controls Compliance Practices Benchmarks for Higher Education, 2020 Edition allows you to compare your own compliance practices and procedures with peers – and identify areas for improvement. Click here for details.

Posted under: University-Industry Engagement Week

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment